BioSpace News Archive

New data focused on advanced technology innovations for managing type 2 diabetes highlight the positive impact of automated insulin delivery systems and continuous glucose monitoring in improving glycemic control and overall diabetes management.

Dovetail Genomics, a pioneering leader in the development of genomic solutions, announced a new strategic partnership with Australian Genome Research Facility.

NeuroBo Pharmaceuticals, Inc. today announced that it has entered into definitive agreements for the issuance and sale in a private placement of 4,325,701 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $3.93 per share (or per pre-funded warrant in lieu thereof).

ILiAD Biotechnologies, LLC today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.

Edesa Biotech, Inc. announced today that its first-in-class drug candidate has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study.

PolTREG S.A. announces that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care, in a long-term clinical study into the safety and efficacy of lead asset PTG-007.

SOPHiA GENETICS, a cloud-native healthcare technology company and a global leader in data-driven medicine, announced its new Residual Acute Myeloid Application.

Allecra Therapeutics and Acino announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP® within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024.

Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that UNITY® Vitreoretinal Cataract System and UNITY® Cataract System have received U.S. Food and Drug Administration 510 clearance.

OSE Immunotherapeutics SA, announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.